ORTHOPEDIATRICS CORP. Financials OrthoPediatrics Corp.
Equities
KIDS
US68752L1008
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.26 USD | +1.07% |
|
-0.16% | -6.92% |
| Mar. 08 | Truist Securities Adjusts Price Target on OrthoPediatrics to $32 From $31, Maintains Hold Rating | MT |
| Mar. 07 | Transcript : OrthoPediatrics Corp., Q4 2023 Earnings Call, Mar 07, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 774.7 | 806.6 | 1,178 | 909.5 | 759.2 | 719.8 | - | - |
| Enterprise Value (EV) 1 | 774.7 | 806.6 | 1,178 | 909.5 | 759.2 | 719.8 | 719.8 | 719.8 |
| P/E ratio | -50 x | -22.7 x | -71.3 x | 662 x | -35.3 x | -25.6 x | -27.5 x | -35.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 10.7 x | 11.3 x | 12 x | 7.44 x | 5.1 x | 3.68 x | 3.08 x | 2.58 x |
| EV / Revenue | 10.7 x | 11.3 x | 12 x | 7.44 x | 5.1 x | 3.68 x | 3.08 x | 2.58 x |
| EV / EBITDA | -727 x | -137 x | -6,472 x | 4,007 x | 151 x | 83.5 x | 42.5 x | 26.2 x |
| EV / FCF | -26,186,586 x | - | - | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 16,487 | 19,555 | 19,678 | 22,892 | 23,353 | 23,786 | - | - |
| Reference price 2 | 46.99 | 41.25 | 59.86 | 39.73 | 32.51 | 30.26 | 30.26 | 30.26 |
| Announcement Date | 3/4/20 | 3/10/21 | 3/2/22 | 2/28/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 72.55 | 71.08 | 98.05 | 122.3 | 148.7 | 195.4 | 233.9 | 278.5 |
| EBITDA 1 | -1.066 | -5.871 | -0.182 | 0.227 | 5.04 | 8.622 | 16.93 | 27.46 |
| EBIT 1 | -9.077 | -26.76 | -18.02 | -25.4 | -26.75 | -24.9 | -20.96 | -13.62 |
| Operating Margin | -12.51% | -37.64% | -18.38% | -20.77% | -17.99% | -12.74% | -8.96% | -4.89% |
| Earnings before Tax (EBT) 1 | -12.68 | -33.67 | -17.39 | -3.689 | -21.31 | -29.04 | -26.54 | -19.45 |
| Net income 1 | -13.73 | -32.94 | -16.26 | 1.258 | -20.97 | -28.43 | -25.74 | -19.91 |
| Net margin | -18.93% | -46.35% | -16.58% | 1.03% | -14.1% | -14.55% | -11.01% | -7.15% |
| EPS 2 | -0.9400 | -1.820 | -0.8400 | 0.0600 | -0.9200 | -1.183 | -1.102 | -0.8600 |
| Free Cash Flow | -29.58 | - | - | - | - | - | - | - |
| FCF margin | -40.78% | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/4/20 | 3/10/21 | 3/2/22 | 2/28/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 25.08 | 24.81 | 23.42 | 32.93 | 34.95 | 30.99 | 31.59 | 39.56 | 39.97 | 37.61 | 41.22 | 51.74 | 52.83 | 49.63 | 49.38 |
| EBITDA 1 | 0.519 | -0.567 | -1.594 | 2.103 | 1.903 | -2.236 | -2.053 | 2.272 | 3.598 | 1.295 | -1.344 | 3.681 | 4.955 | 1.296 | 0.3515 |
| EBIT 1 | -3.644 | -5.561 | -6.386 | -3.743 | -3.352 | -8.309 | -8.591 | -5.586 | -4.508 | -8.066 | -9.143 | -5.016 | -3.429 | -7.297 | -6.417 |
| Operating Margin | -14.53% | -22.41% | -27.27% | -11.37% | -9.59% | -26.81% | -27.2% | -14.12% | -11.28% | -21.44% | -22.18% | -9.69% | -6.49% | -14.7% | -13% |
| Earnings before Tax (EBT) 1 | -2.489 | -0.166 | -9.417 | -0.772 | 14.4 | -7.897 | -7.38 | -3.287 | -3.742 | -6.903 | -10.17 | -6.061 | -4.458 | -8.326 | -8.367 |
| Net income 1 | -2.197 | 0.072 | -9.1 | -0.333 | 18.54 | -7.849 | -6.806 | -2.886 | -4.591 | -6.691 | -10.06 | -5.825 | -4.34 | -8.204 | -8.099 |
| Net margin | -8.76% | 0.29% | -38.86% | -1.01% | 53.04% | -25.32% | -21.55% | -7.3% | -11.49% | -17.79% | -24.41% | -11.26% | -8.21% | -16.53% | -16.4% |
| EPS 2 | -0.1100 | - | -0.4700 | -0.0200 | 0.8700 | -0.3500 | -0.3000 | -0.1300 | -0.2000 | -0.2900 | -0.4129 | -0.2414 | -0.1843 | -0.3400 | -0.3933 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 3/2/22 | 5/4/22 | 8/3/22 | 10/31/22 | 2/28/23 | 5/1/23 | 7/31/23 | 11/6/23 | 3/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -29.6 | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 11.8 | - | - | - | - | - | - | - |
| Capex / Sales | 16.29% | - | - | - | - | - | - | - |
| Announcement Date | 3/4/20 | 3/10/21 | 3/2/22 | 2/28/23 | 3/6/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
30.26
USD
Average target price
40
USD
Spread / Average Target
+32.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.92% | 720M | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +25.15% | 4.99B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B |
- Stock Market
- Equities
- KIDS Stock
- Financials OrthoPediatrics Corp.
